drugset / Trial / NCT01717664
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104 than from Interferon beta-1a alone.
Timeline
- Start
- 2013-06
- Primary completion
- 2015-12
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 95 mg | Oral |
| Subject | Clofazimine | Small molecule | 10 mg | Oral |
| Subject | Rifabutin | Small molecule | 45 mg | Oral |